Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE
You may also be interested in...
DexCom IPO Assists Firm In Quest For Next-Generation CGMS Approval
DexCom will use part of the $54.9 mil. in net proceeds it expects to garner from an April 14 initial public offering to support ongoing clinical trials for its two continuous blood glucose monitoring systems
DexCom IPO Assists Firm In Quest For Next-Generation CGMS Approval
DexCom will use part of the $54.9 mil. in net proceeds it expects to garner from an April 14 initial public offering to support ongoing clinical trials for its two continuous blood glucose monitoring systems
Novak at Novoste
Alfred Novak becomes president, CEO and director of the brachytherapy device manufacturer Oct. 16, succeeding Bill Hawkins, who left in January to head Medtronic's vascular unit, Medtronic AVE (1"The Gray Sheet" Dec. 24, 2001, p. 7). Novak is chairman of Orbus Medical Technologies and Transurgical, and a founding member of Syntheon LLC. He has served as president and CEO of Biosense, sold to Johnson & Johnson in 1997, from 1996 and 1998, and as CFO of Cordis from 1989 until the company was bought by J&J in 1996...